MA55381A - Pyridazinones et leurs procédés d'utilisation - Google Patents

Pyridazinones et leurs procédés d'utilisation

Info

Publication number
MA55381A
MA55381A MA055381A MA55381A MA55381A MA 55381 A MA55381 A MA 55381A MA 055381 A MA055381 A MA 055381A MA 55381 A MA55381 A MA 55381A MA 55381 A MA55381 A MA 55381A
Authority
MA
Morocco
Prior art keywords
pyridazinones
methods
Prior art date
Application number
MA055381A
Other languages
English (en)
Inventor
Michael Broxson
Gal Marie-Francoise Yveline Coeffet-Le
Matthew H Daniels
Jean-Christophe P Harmange
Mark W Ledeboer
Peter H Mundel
John Francis Reilly
Liron Walsh
Amy Kieu Duyen Westerling-Bui
Maolin Yu
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of MA55381A publication Critical patent/MA55381A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA055381A 2019-03-20 2020-03-18 Pyridazinones et leurs procédés d'utilisation MA55381A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962821178P 2019-03-20 2019-03-20

Publications (1)

Publication Number Publication Date
MA55381A true MA55381A (fr) 2022-01-26

Family

ID=72519163

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055381A MA55381A (fr) 2019-03-20 2020-03-18 Pyridazinones et leurs procédés d'utilisation

Country Status (11)

Country Link
US (1) US20220152031A1 (fr)
EP (1) EP3941475A4 (fr)
JP (2) JP7571039B2 (fr)
CN (2) CN113939295B (fr)
AU (2) AU2020240059B2 (fr)
CA (1) CA3132580A1 (fr)
IL (2) IL321764A (fr)
MA (1) MA55381A (fr)
MX (2) MX2021011316A (fr)
SG (1) SG11202109568TA (fr)
WO (1) WO2020191056A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3075727A1 (fr) 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones et leurs procedes d'utilisation
MD3852533T2 (ro) * 2018-09-18 2024-08-31 Gfb Abc Llc Piridazinone și metode de utilizare ale acestora
WO2020191056A1 (fr) * 2019-03-20 2020-09-24 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation
SG11202110585SA (en) 2019-04-11 2021-10-28 Goldfinch Bio Inc Spray-dried formulation of a pyridazinone trpc5 inhibitor
AU2021302090B2 (en) * 2020-07-03 2024-01-18 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound and use thereof
CN117940417A (zh) * 2021-09-10 2024-04-26 南京明德新药研发有限公司 卤素取代的哒嗪酮类化合物及其应用
CN114235972B (zh) * 2021-10-28 2023-08-22 乳源东阳光药业有限公司 一种测定利格列汀杂质rbp-1含量的方法
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
WO2024027752A1 (fr) * 2022-08-05 2024-02-08 武汉朗来科技发展有限公司 Composition pharmaceutique comprenant un composé hétérocyclique, procédé de préparation associé et utilisation correspondante
CN118834210A (zh) 2023-04-25 2024-10-25 中国科学院上海药物研究所 哒嗪酮类trpc4/5抑制剂及其用途
WO2024249254A2 (fr) * 2023-05-26 2024-12-05 Maze Therapeutics, Inc. Procédés d'utilisation d'inhibiteurs d'apol1

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945857A (en) * 1955-05-06 1960-07-19 Monsanto Chemicals Pyridazinones
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
CA2099743A1 (fr) * 1992-07-02 1994-01-03 Akihiko Ishida Derives de la pyridazinone et procedes pour leur preparation
HUT76280A (en) * 1993-12-29 1997-07-28 Fujisawa Pharmaceutical Co Pyrazolopyridine derivatives, pharmaceutical compositions containing them, process for proiducing them and their use
JPH09216883A (ja) * 1996-02-09 1997-08-19 Fujisawa Pharmaceut Co Ltd ピラゾロピリジン化合物および該化合物を含有する医薬
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
WO2003057689A1 (fr) * 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Composes aminopyrimidine, procedes de preparation de ces composes et compositions pharmaceutiques les contenant
WO2004022540A2 (fr) * 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Compose de pyridazinone et son utilisation pharmaceutique
AU2003901647A0 (en) * 2003-04-04 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Novel Condensed Furan Compounds and Pharmaceutical Use Thereof
CA2553969A1 (fr) * 2004-01-23 2005-08-04 Amgen Inc. Ligands de recepteur vanilloide et leur utilisation dans le cadre de traitements
WO2006044504A1 (fr) * 2004-10-13 2006-04-27 Merck & Co., Inc. Antagonistes aux récepteurs de cgrp
CA2594998A1 (fr) * 2005-01-25 2006-08-03 Neurogen Corporation Analogues de pyridazinyl-et de pyrimidinyl-quinolin-4-ylamine substitues
CN101321525B (zh) * 2005-12-01 2013-01-30 霍夫曼-拉罗奇有限公司 作为l-cpt1抑制剂的杂芳基取代的哌啶衍生物
JP2009518442A (ja) * 2005-12-05 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシド加水分解酵素インヒビターとして有益な置換ピラゾール化合物
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
WO2009114677A1 (fr) * 2008-03-13 2009-09-17 Bristol-Myers Squibb Company Dérivés de la pyridazine inhibiteurs du facteur xia
WO2009117157A1 (fr) * 2008-03-20 2009-09-24 Amgen Inc. Modulateurs d’aurora kinase et procédé d’utilisation
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
US20170146554A1 (en) * 2009-06-10 2017-05-25 Masanori Hara Method for test on diabetic nephropathy
GB201222711D0 (en) * 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
UY35424A (es) * 2013-03-14 2014-10-31 Hydra Biosciences Inc Xantinas sustituidas y métodos para su uso
MA36055B1 (fr) * 2013-06-27 2015-12-31 Univ Mohammed V Souissi Dérivés des pyridazin-3(2h)-ones, préparation , activités pharmacologiques et biologiques
EP2881390A1 (fr) * 2013-12-04 2015-06-10 Sanofi Dérivés de thienométhylpipérazine en tant qu'inhibiteurs d'époxyde-hydrolase soluble
CN103772352B (zh) * 2014-01-16 2017-01-18 四川百利药业有限责任公司 哒嗪酮类衍生物及其制备方法和用途
EP3180340B1 (fr) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Dérivés de pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione
CA3075727A1 (fr) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones et leurs procedes d'utilisation
EA202092590A1 (ru) * 2018-04-30 2021-04-08 Рибон Терапьютикс Инк. Пиридазиноны в качестве ингибиторов parp7
JP2021527636A (ja) * 2018-06-04 2021-10-14 オハイオ・ステイト・イノベーション・ファウンデーション Ｅａａｔ２活性化因子およびその使用方法
MD3852533T2 (ro) * 2018-09-18 2024-08-31 Gfb Abc Llc Piridazinone și metode de utilizare ale acestora
WO2020191056A1 (fr) * 2019-03-20 2020-09-24 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation

Also Published As

Publication number Publication date
IL286481B1 (en) 2025-08-01
EP3941475A1 (fr) 2022-01-26
MX2025012087A (es) 2025-11-03
MX2021011316A (es) 2021-10-13
US20220152031A1 (en) 2022-05-19
WO2020191056A8 (fr) 2021-09-30
IL286481A (en) 2021-12-01
AU2020240059B2 (en) 2025-10-23
WO2020191056A1 (fr) 2020-09-24
AU2026200453A1 (en) 2026-02-12
JP2025020132A (ja) 2025-02-12
CN113939295B (zh) 2025-05-16
SG11202109568TA (en) 2021-10-28
CA3132580A1 (fr) 2020-09-24
AU2020240059A1 (en) 2021-10-28
JP7571039B2 (ja) 2024-10-22
IL286481B2 (en) 2025-12-01
IL321764A (en) 2025-08-01
CN120393027A (zh) 2025-08-01
EP3941475A4 (fr) 2023-01-25
JP2022525506A (ja) 2022-05-17
CN113939295A (zh) 2022-01-14

Similar Documents

Publication Publication Date Title
EP3941475A4 (fr) Pyridazinones et leurs procédés d'utilisation
EP3684364A4 (fr) Pyridazinones et leurs procédés d'utilisation
EP3852533A4 (fr) Pyridazinones et leurs procédés d'utilisation
EP4037695A4 (fr) Compositions oligonucléotidiques et leurs procédés d'utilisation
MA55890A (fr) Modulateurs de thr-beta et leurs procédés d'utilisation
EP3958872A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3775203A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
MA55136A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3968999A4 (fr) Inhibiteurs de fgfr et leurs procédés d'utilisation
MA54538A (fr) Inhibiteurs d'apol1 et leurs procédés d'utilisation
MA55885A (fr) Chélateurs macrocycliques et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
EP3911648A4 (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP4022069A4 (fr) Arn circulaires modifiés et leurs procédés d'utilisation
EP3911640A4 (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP3790572A4 (fr) Variants du récepteur de l'activine de type iia et leurs procédés d'utilisation
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
EP3893917A4 (fr) Compositions d'il-15 et leurs procédés d'utilisation
MA56457A (fr) Modulateurs de hsd17b13 et leurs procédés d'utilisation
MA51837A (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
EP4034605A4 (fr) Compositions de polissage et leurs procédés d'utilisation
EP3836971A4 (fr) Conjugués et leurs procédés d'utilisation
EP3688373A4 (fr) Brûleurs et leurs procédés d'utilisation
EP3965776A4 (fr) Compositions oligosaccharidiques et leurs procédés d'utilisation